63093-41-4

Basic information

• Product Name: ethyl pent-4-ynoate
• Synonyms: ethyl pent-4-ynoate;Ethyl 4-pentynoate;4-(Ethoxycarbonyl)-1-butyne
• CAS NO: 63093-41-4
• Molecular Formula: C₇H₁₀O₂
• Molecular Weight: 126.1531
• Mol File: 63093-41-4.mol

Chemical Properties

• Boiling Point: 162.1°Cat760mmHg
• Flash Point: 50.9°C
• Appearance: /
• Density: 0.96g/cm³
• Vapor Pressure: 2.2mmHg at 25°C
• Refractive Index: 1.432
• CAS DataBase Reference: ethyl pent-4-ynoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl pent-4-ynoate(63093-41-4)
• EPA Substance Registry System: ethyl pent-4-ynoate(63093-41-4)

Safety Data

• Hazardous Substances Data: 63093-41-4(Hazardous Substances Data)

Usage

Uses

Used in Food and Beverage Industry:
Ethyl pent-4-ynoate is used as a flavoring agent for its pleasant aroma and fruity, banana-like odor. It is often used in the production of artificial fruit flavors, enhancing the taste and aroma of various food and drink products.
Used in Perfume and Fragrance Industry:
Ethyl pent-4-ynoate is also used in the manufacturing of perfumes and fragrances due to its pleasant aroma. It contributes to the creation of various scent profiles, adding depth and complexity to fragrance compositions.
It is important to handle and store ethyl pent-4-ynoate carefully, as it is flammable and can cause irritation to the skin, eyes, and respiratory system if not handled properly.

InChI:InChI=1/C7H10O2/c1-3-5-6-7(8)9-4-2/h1H,4-6H2,2H3

Upstream product

• 141-78-6 ethyl acetate 
• 106-96-7 propargyl bromide 
• 5390-04-5 pent-1-yn-5-ol 
• 491862-29-4 2-ethoxycarbonyl-2-(2-propynyl)malonic acid diethyl ester 
• 64-17-5 ethanol 
• 6089-09-4 4-pentynoic acid 
• 17920-23-9 diethyl propargylmalonate 
• 55183-44-3 4-pentynoic chloride 

Downstream Products

• 1487-15-6 2-Methyl-4,5-dihydrofuran 
• 217967-18-5 ethyl trans-5-(bis(pentafluorophenyl)boryl)-4-pentenoate 
• 1289154-49-9 (E)-8-(α-acetyloxy-4'-methoxybenzylidenyl)-5-oxoindolizidine 
• 1289154-41-1 N-allyl-5-(4-methoxyphenyl)-4-pentynamide 
• 1289154-45-5 N-(1-hexen-3-yl)-5-(4-methoxyphenyl)-4-pentynamide 
• 1289154-24-0 C₁₇H₁₉NO₃ 
• 1314451-24-5 C₁₇H₁₃IN₂ 
• 1314451-26-7 C₁₇H₁₁Cl₂IN₂ 
• 1314451-28-9 C₁₈H₁₅IN₂O 
• 876049-26-2 5-(4-(trifluoromethyl)phenyl)pent-4-ynoic acid 
• 1314451-06-3 2-(4-phenylbut-3-ynyl)-1H-benzo[d]imidazole 
• 1314451-08-5 5,6-dichloro-2-(4-phenylbut-3-ynyl)-1H-benzo[d]imidazole 

Relevant articles and documents

DDX3X inhibitors, an effective way to overcome HIV-1 resistance targeting host proteins

The huge resources that had gone into Human Immunodeficiency virus (HIV) research led to the development of potent antivirals able to suppress viral load in the majority of treated patients, thus dramatically increasing the life expectancy of people living with HIV. However, life-long treatments could result in the emergence of drug-resistant viruses that can progressively reduce the number of therapeutic options, facilitating the progression of the disease. In this scenario, we previously demonstrated that inhibitors of the human DDX3X helicase can represent an innovative approach for the simultaneous treatment of HIV and other viral infections such as Hepatitis c virus (HCV). We reported herein 6b, a novel DDX3X inhibitor that thanks to its distinct target of action is effective against HIV-1 strains resistant to currently approved drugs. Its improved in vitro ADME properties allowed us to perform preliminary in vivo studies in mice, which highlighted optimal biocompatibility and an improved bioavailability. These results represent a significant advancement in the development of DDX3X inhibitors as a novel class of broad spectrum and safe anti-HIV-1 drugs.

Sulfapyridine hapten and artificial antigen as well as preparation method and application thereof

The invention relates to sulfapyridine hapten and artificial antigen as well as a preparation method and application thereof. The structure of the sulfapyridine hapten is shown as a formula (1), wherein the R1 and R2 are hydrogen, methyl or methoxyl; m is

NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS

The present invention discloses compounds according to Formula (I): (I). Wherein R1, R2, R5 and Cy are as defined herein. The present invention relates to compounds, methods for the production of said compounds, pharmaceutical compositions comprising said compounds and methods for the prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases, pain, fibrosis and/or proliferative diseases by administering said compounds.

GOLD (I)-PHOSPHINE 1,2,3-TRIAZOLE DERIVATIVES WITH ANTIOBIOTIC PROPERTIES

The present invention relates to gold (l)-phosphine 1,2,3-triazole compounds, and their use in a human or animal medicine. The present invention also relates to using such compounds for the prevention and/or treatment of an infection, i.e. inhibitors of growth of Gram-positive and/or Gram-negative bacteria. On another aspect the invention relates to the synthesis of the gold (l)-phosphine compounds of the invention and to their synthesis intermediates. The present invention finds applications in the medical, veterinary and/or chemical fields.

Single-Molecule Observation of the Intermediates in a Catalytic Cycle

The development of catalysts benefits from knowledge of the intermediate steps that accelerate the transformations of substrates into products. However, key transient species are often hidden in ensemble measurements. Here, we show that a protein nanoreac

An effective synthetic entry to fused benzimidazoles via iodocyclization

A protocol for the synthesis of the fused heterocyclic polycyclic compounds pyrrole[1,2-a]benzimidazoles, piperidine[1,2-a]benzimidazoles and oxa-fused benzimidazoles using iodine and silver nitrate by an exo-dig or endo-dig cyclization pathway at room te

Alkyne-mediated domino hydroformylation/double cyclization: Mechanistic insight and synthesis of (±)-tashiromine

A novel domino reaction, alkyne-mediated domino hydroformylation/double cyclization, has been developed for rapid preparation of indolizidine type alkaloids. DFT calculations were applied for rationales of reactivity and selectivity. A concise synthesis of tashiromine as the application of the methodology is also reported.

Intramolecular PIFA-mediated alkyne amidation and carboxylation reaction

(Chemical Equation Presented) The hypervalent iodine reagent PIFA promotes the intramolecular electrophilic cyclization of easily accessible alkynylamides and alkynyl carboxylic acids, leading to the formation of pyrrolidinone and lactone skeletons, respe

Synthesis of 3-arylpropenyl, 3-arylpropynyl and 3-arylpropyl 2-azetidinones as cholesterol absorption inhibitors: Application of the palladium-catalyzed arylation of alkenes and alkynes

A series of 3-(3'-arylpropenyl)-2-azetidinones 8a-8k and 3-(3'-arylpropynyl)-2-azetidinones 16m-16p were prepared by the palladium-catalyzed arylation of 3-(3'-propenyl)-2-azetidinone 7, or by arylation of 4-pentenoic acid, or via ethyl 4-pentynoate followed by 2-azetidinone ring construction. The unsaturated 2-azetidinones were transformed to their saturated analogs 9a-9p by catalytic hydrogenation. Azetidinones 8a-8k, 9a-9p, and 16m-16p were evaluated for their biological activity as cholesterol absorption inhibitors in hamsters. (C) 2000 Elsevier Science Ltd.

New anionic cyclization of 4- and 5-alkynylamines: Synthesis of 2-Benzylidene pyrrolidines and piperidines

Treatment of 4- and 5-alkynylamines with 0.5-1.2 equiv. of butyllithium brought about a facile anionic cyclization, giving the corresponding enamine pyrrolidines and piperidines having an exo double bond in high yields. Treatment of 4-alkynamides with lit